Further research is essential to discover new strains, optimize dosing regimens, confirm safety, and validate health claims through robust clinical trials
The result is a streamlined drug discovery process that quickly and cheaply identifies the best anti-DSIP antibody drugs.
Wang Y-F, Hsu Y-J, Wu H-F, Lee G-L, Yang Y-S, Wu J-Y, et al
Overall, the primary composite endpoint occurred in 331 patients of 1767 (18.7%) on Ozempic (1 mg) and 410 patients of 1766 (23.2%) on placebo (HR, 0.76 [95% CI: 0.66-0.88] P =0.0001 for superiority)
Body composition was measured at the start of the study, at three months, and again at six months, using the InBody 570, a professional-grade analyzer that utilizes multi-frequency bioelectrical impedance analysis (BIA)